Meeting
2022 ASCO Annual Meeting
Body weight (BW) response timing to anamorelin (ANAM) in advanced non–small cell lung cancer (NSCLC)–associated cachexia.
Authors
Richard J.E. Skipworth
Clinical Surgery, University of Edinburgh, Edinburgh, United Kingdom
Richard J.E. Skipworth , Declan Walsh , Daniela D. Rotaru , Gianluca Ballinari , David C. Currow
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01387269, NCT01387282
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12110)
DOI
10.1200/JCO.2022.40.16_suppl.12110
Abstract #
12110
Poster Bd #
354
Abstract Disclosures
Similar Posters
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2.
First Author: Jennifer S. Temel
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): Post-hoc analysis of two phase III studies.
First Author: David Christopher Currow
Poster
2016 ASCO Annual Meeting
Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (< 20 kg/m2): A pooled efficacy data analysis of two phase 3 studies.
First Author: David Christopher Currow
Poster
2014 Palliative and Supportive Care in Oncology Symposium
Subgroup analysis of ECOG2 patients from ROMANA 2: A phase III study of anamorelin in NSCLC patients with cachexia.
First Author: Amy Pickar Abernethy